Could a combo eye treatment cut down on needle pokes?
NCT ID NCT01295112
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether adding a dexamethasone implant (Ozurdex) to standard bevacizumab (Avastin) eye injections could reduce the number of injections needed for people with non-ischemic central retinal vein occlusion. Sixty-eight participants received either Avastin plus a sham procedure or Avastin plus Ozurdex. The main goal was to count how many Avastin injections were needed over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bevacizumab (Avastin) and dexamethasone (Ozurdex) eye implants/injections
- What this could lead to
- If it works, this could mean fewer eye injections for people with central retinal vein occlusion, making treatment easier.
- What could go wrong
- This is a small, completed Phase 2/3 trial with only 68 participants, so results may not apply to everyone. Adding Ozurdex may not reduce injections enough or could cause side effects like increased eye pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
68 people
The number who actually took part.
- Start date
-
May 2011
- Finished
-
Oct 2015
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. male or female subjects (aged 18 or older); 2. provide written informed consent and sign/date a health information release; 3. women of childbearing potential must be willing to practice effective contraception for the duration of the study. Exclusion Criteria: 1. any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results; 2. use of systemic steroids within 1 month prior to Baseline Visit (Visit 1) or anticipated use at any time during the study (inhaled and intranasal steroids are allowed); 3. sitting systolic blood pressure equal to or greater than 160 mmHg or diastolic blood pressure equal to or greater than 100 mmHg at the Baseline Visit (Visit 1); 4. use of warfarin, heparin, enoxaparin or similar anticoagulants within 2 weeks prior to Baseline Visit (Visit 1) or anticipated use at any time during the study; 5. known allergy or hypersensitivity to the study medications or their components; 6. previous enrollment in an Ozurdex® clinical trial or previous use of an Ozurdex® implant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-ischemic central retinal vein occlusion are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Retina Associates
Dallas, Texas, 75231, United States